PMID

Data

Article Title

Organization

Non-kinase targets of protein kinase inhibitors.

The University Of Sydney

Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.

Paris-Sud University

Recent developments of 2-aminothiazoles in medicinal chemistry.

Sree Chaitanya College

Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).

Icahn School Of Medicine At Mount Sinai

Synthesis and identification of unprecedented selective inhibitors of CK1e.

Instituto Universitario De Bio-Org£Nica Antonio Gonz£Lez (Iubo-Ag)

Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1d ande with nanomolar inhibitory activity on cancer cell proliferation.

Ulm University Hospital

Ligand-protein interactions of selective casein kinase 1d inhibitors.

Pfizer

Structure-based optimization of oxadiazole-based GSK-3 inhibitors.

Technische Universit£T Darmstadt

Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.

TBA

Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Cellzome

Structural basis for the potent and selective inhibition of casein kinase 1 epsilon.

Amgen

Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3a.

Technische Universit£T Darmstadt

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

University Of Oxford

Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor.

Amgen

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas.

Technische Universit£T Darmstadt

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors

Roche Palo Alto

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

Roche Palo Alto

Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

National Human Genome Research Institute

3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.

Eberhard-Karls University

 

Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II

TBA

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Johnson & Johnson Pharmaceutical Research And Development

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

Johnson & Johnson Pharmaceutical Research And Development

A small molecule-kinase interaction map for clinical kinase inhibitors.

Ambit Biosciences

Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

Johnson & Johnson Pharmaceutical Research & Development

Kinase Chemodiversity from the Arctic: The Breitfussins.

Uit - The Arctic University Of Norway

Small molecule modulators targeting protein kinase CK1 and CK2.

China Pharmaceutical University

Decreasing the CYP2D6 contribution to metabolism of a CK1? inhibitor.

Sanofi Us

ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.

University Of Florida

Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) ?/?.

Ulm University Hospital

Development of dual casein kinase 1?/1? (CK1?/?) inhibitors for treatment of breast cancer.

Scripps Florida

Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.

Novartis Institutes For Biomedical Research

Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity.

Mclean Hospital

In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.

Abbott Laboratories

Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.

University Of Bologna